Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia by Fedullo, Al et al.
312 haematologica | 2019; 104(2)
Received: April 26, 2018.
Accepted: August 30, 2018.
Pre-published: September 6, 2018.
©2019 Ferrata Storti Foundation
Material published in Haematologica is covered by copyright.
All rights are reserved to the Ferrata Storti Foundation. Use of
published material is allowed under the following terms and
conditions: 
https://creativecommons.org/licenses/by-nc/4.0/legalcode. 
Copies of published material are allowed for personal or inter-
nal use. Sharing published material for non-commercial pur-
poses is subject to the following conditions: 
https://creativecommons.org/licenses/by-nc/4.0/legalcode,
sect. 3. Reproducing and sharing published material for com-
mercial purposes is not allowed without permission in writing
from the publisher.
Correspondence: 
chiaretti@bce.uniroma1.it  or
rfoa@bce.uniroma1.it
Haematologica 2019
Volume 104(2):312-318
ARTICLE Acute Lymphoblastic Leukemia
doi:10.3324/haematol.2018.196055
Check the online version for the most updated
information on this article, online supplements,
and information on authorship & disclosures:
www.haematologica.org/content/104/2/312
Ferrata Storti Foundation
Introduction
The Philadelphia (Ph) chromosome derives from the t(9;22)(q34;q11) and leads to
a BCR-ABL1 rearrangement.1 The incidence of this chromosomal change in acute
lymphoblastic leukemia (ALL) increases with age, being detected in 25% of adults
and in about 50% of elderly patients.2 Prior to the advent of tyrosine kinase
inhibitors, the outcome of Ph+ ALL patients was extremely poor,3-5 and the only
To shed light onto the molecular basis of Philadelphia chromo-some-positive acute lymphoblastic leukemia and to investigatethe prognostic role of additional genomic lesions, we analyzed
copy number aberrations using the Cytoscan HD Array in 116 newly
diagnosed adult patients with Philadelphia chromosome-positive acute
lymphoblastic leukemia enrolled in four different GIMEMA protocols,
all based on a chemotherapy-free induction strategy. This analysis
showed that patients with Philadelphia chromosome-positive acute
lymphoblastic leukemia carry an average of 7.8 lesions/case, with dele-
tions outnumbering gains (88% versus 12%). The most common dele-
tions were those targeting IKZF1, PAX5 and CDKN2A/B, which were
detected in 84%, 36% and 32% of cases, respectively. Patients carrying
simultaneous deletions of IKZF1 plus CDKN2A/B and/or PAX5 had a sig-
nificantly lower disease-free survival rate (24.9% versus 43.3%; P=0.026).
The only IKZF1 isoform affecting prognosis was the dominant negative
one (P=0.003). Analysis of copy number aberrations showed that 18%
of patients harbored MEF2C deletions, which were of two types, differ-
ing in size: the longer deletions were associated with the achievement of
a complete molecular remission (P=0.05) and had a favorable impact on
disease-free survival (64.3% versus 32.1% at 36 months; P=0.031). These
findings retained statistical significance also in multivariate analysis
(P=0.057). KRAS deletions, detected in 6% of cases, were associated
with the achievement of a complete molecular remission (P=0.009).
These results indicate that in adults with Philadelphia chromosome-pos-
itive acute lymphoblastic leukemia a detailed evaluation of additional
deletions - including CDKN2A/B, PAX5, IKZF1, MEF2C and KRAS - has
prognostic implications and should be incorporated in the design of
more personalized treatment strategies.
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ABSTRACT
possibility of a cure was allogeneic stem cell transplanta-
tion (HSCT), when feasible.6,7 The introduction of tyrosine
kinase inhibitors, administered with low doses or without
chemotherapy during induction, followed by consolida-
tion chemotherapy and HSCT has markedly improved the
management and outcome of adult Ph+ ALL patients,
with survival rates at 5 years now approaching 50%.8-17
Different biological features - the type of fusion tran-
script (i.e. p190 or p210),18 the persistence and/or reappear-
ance of minimal residual disease (MRD),19,20 additional
genomic deletions (particularly IKZF1, and to a lesser
extent CDKN2A/B and PAX521-24) - and the presence of
mutations at relapse are associated with a worse
outcome.25-27 However, a broad and refined biological algo-
rithm that could help to optimize treatment strategies and
define better whether some patients could be spared
intensive treatment, including HSCT, has so far not been
proposed.
To this end, in the present study we investigated copy
number aberrations (CNA) in 116 newly diagnosed adult
Ph+ ALL patients to identify additional molecular lesions
with the aim of improving patients’ stratification and
management.
Methods
Experimental strategy 
Bone marrow and/or peripheral blood samples from 116
patients (Table 1) with newly diagnosed Ph+ ALL enrolled in four
GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) trials
were analyzed (Online Supplementary Table S1). The study was car-
ried out in four phases (Online Supplementary Figure S1): (i) CNA
analysis of 116 samples by Cytoscan; (ii) multiplex ligation-depen-
dent probe amplification analysis; (iii) validation of MEF2C dele-
tions by digital droplet (dd) polymerase chain reaction (PCR); and
(iv) MEF2C and KRAS mutational screening.
This study was approved in the context of an Associazione
Italiana per la Ricerca sul Cancro (AIRC) project (10007) with
Institutional Review Board number 2182/16.06.2011.
Copy number aberration analysis
CNA were analyzed using CytoScan® HD Arrays (Affymetrix,
Santa Clara, CA, USA) and Chromosome Analysis Suite (ChAS)
software. Germline material from five paired samples was also
evaluated. Recurrent deletions were validated with the Salsa
MLPA P335 ALL-IKZF1 kit (MRC-Holland, Amsterdam, the
Netherlands)28,29 (Online Supplementary Data). Statistical analyses on
clinical correlates are described in the Online Supplementary Data.
Digital droplet polymerase chain reaction assays
MEF2C deletions were validated by ddPCR using the QX200TM
Droplet DigitalTM PCR System (BioRad, Hercules, CA, USA) and
QuantaSoft Analysis Pro software according to the manufacturer's
instructions (Online Supplementary Data).
Mutational screening
Sanger sequencing of PCR products for MEF2C and KRAS
exons (Online Supplementary Table S2) was performed with the
ABI-Prism 3500 sequencer (Applied Biosystem, Life Technologies,
Foster City, CA, USA) (Online Supplementary Data).
Results
Copy number aberration analysis
CNA analysis revealed 7.8 aberrations/patient (range: 0-
28), the majority being losses (88%) with only 12% gains,
both spanning from whole chromosomes to focal
lesions;22,23,30-32 no differences were recorded among trials
(Figure 1A).
Gross chromosomal lesions were found in 42% of
cases: the majority were losses of chromosome 7 (18.1%),
followed by monosomy of chromosome 9 or 9p deletion
(9%) and gain of 1q (7.7%) (Figure 1B, Online
Supplementary Table S3). Smaller deletions - limited to one
to three genes and defined as focal - were found in 56% of
cases.
The most frequently deleted region involved the 7p12
cytoband comprising IKZF122,23,33,34 which was detected in
97 cases (84%).
PAX5 was deleted in 43 patients (36.2%), while 37
(31.9%) had deletions of CDKN2A/B. MLLT3, BTG1,
BTLA, CD200 and RB1 were deleted in 30, 27, 21, 17 and
16 cases, respectively (25.9%, 23%, 18.1%, 17.2%,
14.6%, and 13.8%) (Figure 1C).
IKZF1 deletions (ΔIKZF1) occurred together with
CDKN2A/B and/or PAX5 deletions in 45/97 cases (46.4%)
and are defined as ΔIKZF1+CDKN2A and/or PAX5 (Figure
1D): this subset displayed similar lesions to those recently
described by Stanulla and colleagues.35 With regard to
potential interactions, we found a significant association
between IKZF1 and PAX5 deletions (P=0.01), but not with
CDKN2A.
Multiplex ligation-dependent probe amplification con-
firmed IKZF1, PAX5, CDKN2A, BTG1, EBF1, ETV6 and
RB1 lesions, and allowed evaluation of IKZF1 isoforms.
These isoforms were grouped into four classes:24,36 wild-
type, dominant-negative (comprising Δ4-7 cases, 29.8%),
haploinsufficient (including all cases harboring a deletion
that involves exon 2 - i.e. Δ2-7, Δ2-8, Δ2-3, Δ1-3 - or the
whole gene, 57.7%) and miscellaneous (remaining cases,
11.3%).
Identification of novel lesions
CNA analysis highlighted additional genomic lesions
(Table 2, Online Supplementary Table S4). We focused in
particular on MEF2C and KRAS deletions since these had
prognostic significance (see below). MEF2C deletions
were detected in 21 patients (18.1%) and differed in size.
According to the length of intron 1-2 losses, deletions
were grouped into two categories. One category - detect-
ed in 14 cases (67% of MEF2C deleted cases) - was char-
acterized by a larger minimal common region (6.2 Kb)
involving introns 1-2 and exon 2 (the first codifying exon),
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Table 1. Patients’ clinical features.
                                                                                Patients (n=116)
Gender (male/female)                                                                   55/61
Age, years (range)                                                                   51.1 (18.9-89)
Median white cell count x 109/L (range)                            25.4 (1.7-597)
Median hemoglobin g/dL (range)                                          9.6 (4-16.3)
Median platelet count x 109/L (range)                                   50 (4-333)
Fusion transcript (p190/p210/p190-210)¥                                 70/29/16
Complete molecular response* yes/no                                     17/99
*As per protocol definition; ¥information missing for one patient.
defined ΔMEF2C-long. The other category, detected in
seven patients, was smaller (5.4 Kb) and involved only
exon 2, and was called ΔMEF2C-short (Figure 2A). ddPCR
confirmed MEF2C lesions in all cases. No MEF2C muta-
tions were identified.
KRAS deletions (ΔKRAS) were detected in seven cases
(6%); the focal lesion of KRAS started in the 5’ untranslat-
ed region and ended in intron 1-2, involving the first non-
codifying exon (Figure 2B). The minimal common region
consisted of 135 Kb. KRASwas not affected by mutations.
Impact of known and novel deletions on complete
molecular response achievement and disease-free
survival
We did not find significant differences between patients
with ΔIKZF1 and IKZF1 wild-type cases with regard to
achievement of complete molecular response (CMR) or
disease-free survival (DFS) (Online Supplementary Figure
S2). Further stratification according to IKZF1 isoforms
showed that patients with the dominant-negative isoform
had a lower DFS rate (23.3%; P=0.039) compared to
patients with the other isorforms, particularly wild-type
(53.3%; P=0.016) and haploinsufficient cases (40.3%;
P=0.015); the DFS rate of the miscellaneous group (34.1%)
did not differ significantly from that of the dominant-neg-
ative cases (Figure 3A). These differences were not statis-
tically significant in the overall survival analysis (Figure
3B).
We also investigated the outcome of ΔIKZF1+CDKN2A
and/or PAX5 cases. The CMR rate did not differ between
ΔIKZF1+CDKN2A and/or PAX5 and ΔIKZF1-only cases;
contrariwise, ΔIKZF1+CDKN2A and/or PAX5 patients
had a significantly worse DFS than ΔIKZF1-only cases
(43.3% versus 24.9%; P=0.026) (Figure 3C) and an inferior
overall survival (62.6% versus 40.2%; P=0.02) (Figure 3D).
The presence of ΔMEF2C-long was associated with a
higher rate of CMR achievement (P=0.05); this effect was
not influenced by the protocol or the tyrosine kinase
inhibitor used (imatinib or dasatinib). Furthermore,
ΔMEF2C-long cases were also associated with a signifi-
A.L. Fedullo et al.
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Figure 1. Overall load and incidence of genetic lesions in Philadelphia chromosome-positive acute lymphoblastic leukemia. (A) Distribution of copy number aber-
rations in the whole cohort and across different protocols. (B) Percentages of gross chromosomal aberrations. (C) Percentages of deletions of known genes in the
whole cohort (n=116) and in the different studies analyzed. (D) Heatmap of IKZF1, CDKN2A/B, and PAX5 deletions in the whole cohort.
A
B C
D
Table 2. Minimal common region (MCR) of identified focal lesions.
Deleted gene          N. of patients (%)                   MCR (hg19)
FOCAD                                  29 (25)                      chr9: 20685149 - 20759956
CDK6                                   24 (20.7)                    chr7: 92456635 - 92266647
PTPRD                                 21 (18.1)                      chr9: 8153932 - 8854489
MEF2C                                 21 (18.1)                     chr5:88122179 - 88127630
BTLA                                    21 (18.1)                   chr3:112154702 - 112217769
JAK2                                     20 (17.2)                      chr9: 5123013 - 5234403
ADD3                                   18 (15.5)                 chr10: 111795029 - 111853667
SLX4IP                                 17 (14.6)                   chr20: 10417444 - 10451891
CD200                                  17 (14.6)                   chr3:112054292 - 112217769
HBS1L                                  16 (13.7)                  chr6: 135375338 - 135418257
ATP10A                                  14 (12)                     chr15: 26055568 - 26103185
TOX                                        8 (6.9)                       chr8:60028851 - 60110235
KRAS                                        7 (6)                       chr12: 25402194 - 25537468
ARHGAP24                              7 (6)                        chr4:86493655 - 86436188
EBF1                                      6 (5.1)                    chr5: 158440156 - 158164599
LEF1                                       5 (4.3)                     chr4:109034392 - 109084557
MDM2                                    5 (4.3)                      chr12:69159076 - 69205287
TCF12                                    4 (3.4)                      chr15:57294905 - 57399047
ERG                                        2 (1.7)                      chr21:39772775 - 39788683
cantly better DFS (64.3% versus 32.1%; P=0.031) (Figure
4A) and overall survival (77.9% versus 48.4%; P=0.036)
(Figure 4B).
Lastly, ΔKRAS was more frequently found in patients
who obtained a CMR (24% versus 3%; P=0.009), but this
finding did not have an impact on DFS.
Prognostic impact of known and novel genomic lesions
in univariate and multivariate analyses
In univariate analysis, ΔMEF2C-long and ΔKRAS had an
impact on CMR achievement, while ΔMEF2C-long and
ΔIKZF1+CDKN2A and/or PAX5 influenced DFS (Table 3).
In multivariate analysis for CMR, performed taking into
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Figure 3. Survival probability curves according to IKZF1 status. (A) Disease-free survival and (B) overall survival at 36 months of patients divided according to IKZF1
isoform. (C) Disease-free survival and (D) overall survival at 36 months of ΔIKZF1-only and ΔIKZF1+ CDKN2A and/or PAX5 patients. WT: wild-type; DFS: disease-free
survival; OS: overall survival; CR: complete remission.
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Figure 2. Representation of ΔMEF2C and ΔKRAS. (A) Representation of ΔMEF2C for each patient. Lesions are ordered according to their size: one case had a dele-
tion of the whole gene, one had a deletion that involved only exon 1 spanning from intron 1-2 to the 5’ untranslated region (5’UTR), four had deletions starting from
intron 2-3 and ending at 5’-UTR, thereby involving both exons 2 and 1 (the latter being an untranslated exon), 13 had lesions spanning from intron 2-3 to intron 1-
2, therefore involving exon 2 (the first codifying exon), with six of them harboring a longer intron 1-2 deletion. Lastly, two cases had deletions that involved only intron
1-2. The first 14 cases were considered as ΔMEF2C-long and the remaining as ΔMEF2C-short. (B) Representation of ΔKRAS for each patient. Lesions are ordered
according to their size: in four cases, the deletion encompassed only KRAS itself, whereas in three it involved the short arm of chromosome 12. INTR: intron; EX:
exon; 5’UTR: 5’ untranslated region.
A B
account white blood cell count, age, tyrosine kinase
inhibitor use and the genomic lesions described above, the
only factor that retained statistical significance was
ΔKRAS (P=0.01); a trend was noted for ΔMEF2C-long
deletions (P=0.075) (Table 3). 
In multivariate analysis for DFS, considering ΔMEF2C-
long, ΔIKZF1+CDKN2A and/or PAX5, white blood cell
count and CMR as variables, the factors that had a nega-
tive impact were ΔMEF2C-long (P=0.057) and white
blood cell count (P=0.05), while a trend towards a worse
DFS was observed for ΔIKZF1+CDKN2A and/or PAX5
(P=0.089) (Table 3). HSCT did not affect the prognostic
role of the above-mentioned lesions.
Discussion
The management of adults with Ph+ ALL currently
relies on the use of first,8-10,13-16 second11,12 and third37 gener-
ation tyrosine kinase inhibitors, either alone9-12 or in com-
bination with chemotherapy,8,13-16,37 followed - if feasible
and necessary - by HSCT. These approaches have greatly
improved the outcome of Ph+ ALL: nowadays, virtually
all patients - independent of age - achieve a complete
hematologic remission, coupled to a CMR in a variable
proportion of cases. Nonetheless, in all reported studies
the long-term outcome is in the range of 50% at 5 years;
thus, additional prognosticators capable of better stratify-
A.L. Fedullo et al.
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Table 3. Summary of univariate and multivariate analyses for complete molecular response and disease-free survival for the factors identified.
                                                   Univariate analysis for CMR                                                      Multivariate analysis for CMR
                                                               OR (95% CI)                             P value                                       OR (95%CI)                                    P value
MEF2C deletions                                         0.288 (0.082, 1007)                                 0.051                                            0.259 (0.058, 1.146)                                        0.075
KRAS deletions                                             0.12 (0.024, 0.601)                                 0.009                                            0.068 (0.009, 0.529)                                         0.01
White blood cell count                              0.986 (0.969, 1.003)                                  0.1                                              0.986 (0.966, 1.007)                                        0.188
Age                                                                   1.026 (0.99, 1.063)                                  0.16                                             1.028 (0.985, 1.072)                                        0.205
Imatinib vs. dasatinib                                 0.267 (0.057, 1.248)                                0.093                                            0.296 (0.054, 1.615)                                        0.159
Fusion protein 
(p190 vs. p210 and p190/210)                   1.247 (0.421, 3.693)                                0.691
ΔIKZF1+ CDKN2A and/or PAX5               1.600 (0.599, 4.581)                                0.381
                                                    Univariate analysis for DFS                                                       Multivariate analysis for DFS
                                                                 HR (95% CI)                             P value                                       HR (95%CI)                                    P value
MEF2C deletions                                         0.359 (0.144, 0.891)                                0.027                                            0.417 (0.169-1.028)                                         0.057
ΔIKZF1+ CDKN2A and/or PAX5               1.834 (1.148, 2.929)                                0.011                                            1.608 (0.930, 2.781)                                        0.089
White blood cell count                                  1.002 (1, 1.004)                                    0.065                                                1.003 (1, 1.006)                                            0.050
Age                                                                  1.001 (0.986, 1.017)                                0.866                                              1.01 (0.995-1.028)                                          0.180
CMR                                                                0.423 (0.181-0.987)                                 0.046                                            0.402 (0.167-0.969)                                         0.042
Fusion protein 
(p190 vs. p210 and p190/210)                    0.939 (0.582, 1.515)                                0.797
Imatinib vs. dasatinib                                 1.305 (0.807, 2.109)                                0.277
Allogeneic transplant                                 0.682 (0.362, 1.284)                                 0.23
CMR: complete molecular response; OR: odds ratio; 95% CI: 95% confidence interval; DFS: disease-free survival; HR: hazard ratio.
Figure 4. Survival probability curves according to MEF2C status. (A) Disease-free survival at 36 months of ΔMEF2C versus MEF2C wild-type patients. (B) Overall
survival at 36 months of ΔMEF2C versus MEF2C wild-type patients. WT: wild-type; DFS: disease-free survival; OS: overall survival; CR: complete remission. 
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ing patients into high- and low-risk categories are urgently
needed to further optimize treatment. Moreover, another
unsolved issue is whether all eligible patients should
undergo HSCT,7,17 a procedure still associated with short-
and long-term side effects, as well as treatment-related
mortality. This is particularly important for patients who
obtain a CMR.
To address these issues we sought to identify additional
genomic lesions with prognostic significance in adult Ph+
ALL using high density Cytoscan arrays. We found that
adult Ph+ ALL patients carried an average of 7.8 aberra-
tions each, with deletions outnumbering gains, in line
with other ALL subsets.22,30,38,39 Macro-aberrations were
identified in 48% of cases and micro-aberrations in the
majority of patients: among the latter, the most frequent
was ΔIKZF1, which was detected in 84% of cases. ΔIKZF1
has been regarded as a poor prognostic marker in both
childhood and adult ALL.34,36,39-41 This finding was not,
however, confirmed in our cohort: in fact, the presence of
ΔIKZF1 alone was not associated with a worse DFS. A fur-
ther evaluation of the various IKZF1 isoforms showed
that only the dominant-negative genotype was deleteri-
ous for outcome. In addition, patients with
ΔIKZF1+CDKN2A and/or PAX5, accounting for almost
half the ΔIKZF1 cases, experienced a significantly inferior
DFS (P=0.005) and overall survival (P=0.02), in line with
previous reports on ALL in general.28,29,36,39,42,43
ΔIKZF1+CDKN2A and/or PAX5 also had a prognostic
impact in multivariate analysis; survival analysis was car-
ried out merging all cases enrolled in the different trials
together in order to gain statistical significance.
Recently, studies have been focused on the presence of
additional karyotypic aberrations in Ph+ ALL.44-48 These
studies have highlighted that a high percentage of Ph+ ALL
cases (60-80%) harbor additional chromosomal abnormal-
ities, with the most frequent aberrations involving chro-
mosomes 7, 9, and 14. Patients with additional abnormali-
ties, particularly loss of 9/9p and/or CDKN2A, have a
worse outcome. These results point to the importance of
screening for other molecular markers, and not only IKZF1,
in agreement with our findings on ΔIKZF1+CDKN2A
and/or PAX5. At variance from these reports, our study
also identified novel lesions that had a favorable impact on
outcome. Among these, it is worth mentioning ΔMEF2C,
which occurred in 18.1% of patients and was of two sizes,
a long deletion, encompassing introns 1-2 and exon 2, and
a second, smaller one, involving only exon 2. MEF2C is a
transcription factor involved in B-cell survival and prolifer-
ation whose overexpression is associated with an unfavor-
able prognosis in T-ALL and acute myeloid leukemia.49-52 In
our study, the presence of ΔMEF2C-long was associated
with achievement of a CMR (P=0.05) and with a signifi-
cantly better DFS compared to the remaining cases
(P=0.031) also in a multivariate model; as for IKZF1 dele-
tions, survival analysis was performed merging the whole
cohort because of the sample sizes. ΔMEF2C-long was
widely distributed among cases, with no association with
white blood cell count, age, type of fusion protein or addi-
tional deletions. To our knowledge, this is the first report
that correlates ΔMEF2C-long with prognosis in Ph+ ALL:
Martinelli et al.40 and Mullighan et al.22,41 described ΔMEF2C
in Ph+ ALL, but did not demonstrate a correlation with
outcome. Finally, ΔKRASwas associated with a higher rate
of CMR achievement upon induction (P=0.01), but not
with a better DFS.
In conclusion, we show that additional genetic lesions
can be found at presentation in adult Ph+ ALL patients
and that these lesions have prognostic significance, with
the IKZF1 dominant-negative isoform and
ΔIKZF1+CDKN2A and/or PAX5 negatively affecting out-
come, and ΔMEF2C and ΔKRAS being instead associated
with a more favorable prognosis. Screening for these
genetic lesions should, therefore, be performed at the
time of diagnosis for a more refined prognostic stratifica-
tion, and for a more personalized and tailored manage-
ment of Ph+ ALL patients.
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